Hyperthermia in the treatment of cancer

Field, S. B.; Bleehen, Norman M.

doi:10.1016/s0305-7372(79)80043-2

Cited by 263 publications

(73 citation statements)

References 75 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That is confirmed by experimental results which show that a time interval shorter than 4 h results in a significantly higher TER, reaching the highest TER when RT and HT are given simultaneously [27,38]. In Figure 1 the peak TER value for time intervals 54 h ranges between 1.5 and 2.5 for tumour tissue and TER ranges between 1 and 2.5 for skin tissue [38] which has been confirmed for a range of tumours and normal tissues [11,39,40]. Repair of DNA damage takes up to a few hours, so the increase in TER for time intervals 54 h is likely to represent radiosensitisation by blocking DNA repair in both tumour and normal tissue.…”

Section: Sequence and Time Intervalsupporting

confidence: 71%

Thermoradiotherapy planning: Integration in routine clinical practice

Crezee

Leeuwen

Oei

et al. 2015

International Journal of Hyperthermia

View full text Add to dashboard Cite

Planning of combined radiotherapy and hyperthermia treatments should be performed taking the synergistic action between the two modalities into account. This work evaluates the available experimental data on cytotoxicity of combined radiotherapy and hyperthermia treatment and the requirements for integration of hyperthermia and radiotherapy treatment planning into a single planning platform. The underlying synergistic mechanisms of hyperthermia include inhibiting DNA repair, selective killing of radioresistant hypoxic tumour tissue and increased radiosensitivity by enhanced tissue perfusion. Each of these mechanisms displays different dose-effect relations, different optimal time intervals and different optimal sequences between radiotherapy and hyperthermia. Radiosensitisation can be modelled using the linear-quadratic (LQ) model to account for DNA repair inhibition by hyperthermia. In a recent study, an LQ model-based thermoradiotherapy planning (TRTP) system was used to demonstrate that dose escalation by hyperthermia is equivalent to $10 Gy for prostate cancer patients treated with radiotherapy. The first step for more reliable TRTP is further expansion of the data set of LQ parameters for normally oxygenated normal and tumour tissue valid over the temperature range used clinically and for the relevant time intervals between radiotherapy and hyperthermia. The next step is to model the effect of hyperthermia in hypoxic tumour cells including the physiological response to hyperthermia and the resulting reoxygenation. Thermoradiotherapy planning is feasible and a necessity for an optimal clinical application of hyperthermia combined with radiotherapy in individual patients.

show abstract

Section: Sequence and Time Intervalsupporting

confidence: 71%

Thermoradiotherapy planning: Integration in routine clinical practice

Crezee

Leeuwen

Oei

et al. 2015

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…Although chemotherapy has proven effective for the treatment of many tumor types, survival benefits in malignant glioma patients have been modest [3]. In order to improve the effects of conventional therapies, moderate hyperthermia (MHT) has been combined with chemotherapy or ionizing radiation in the treatment of a variety of tumors as adjuvant therapy [4][5][6][7][8]. MHT typically occurs in a temperature range of 40 to 44°C over times ranging from 30-60 min and is generally nontoxic to cells [7].…”

Section: Introductionmentioning

confidence: 99%

Synergistic chemotherapy by combined moderate hyperthermia and photochemical internalization

Christie

Molina

Gonzales

et al. 2016

Biomed. Opt. Express

View full text Add to dashboard Cite

Combination therapies of photochemical internalization (PCI) and moderate hyperthermia (MHT) were investigated in an in vitro system consisting of human and rat glioma spheroids. PCI using the amphiphilic photosensitizer, AlPcS2a and two anti cancer agents BLM or 5-FU were used. Spheroids were irradiated with λ = 670 nm laser light in an incubator at temperatures ranging from 37 to 44°C. For each temperature investigated, spheroids were divided into 4 groups: control, drug-only, photodynamic therapy (PDT), and PCI. PDT and PCI spheroids were exposed to radiant exposures ranging from 0.3 to 2.5 J cm −2 using an irradiance of 5 mW cm −2 . Toxicity was evaluated from spheroid growth kinetics. The combination of PCI and MHT resulted in significant increases in BLM efficacy at 44°C for both cell line derived spheroids compared to controls at 37°C over the range of radiant exposures examined. 5-FU PCI was ineffective for the human cell line at both 37 and 44°C. L. West, "Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance," Proc. Natl. Acad. Sci. U.S.A. 100(23), 13549-13554 (2003). 31. X. Huang, P. K. Jain, I. H. El-Sayed, and M. A. El-Sayed, "Determination of the minimum temperature required for selective photothermal destruction of cancer cells with the use of immunotargeted gold nanoparticles," Photochem. Photobiol. 82(2), 412-417 (2006). 32.

show abstract

“…Both environmental and intrinsic differences between normal and tumour cells have been invoked as explanations for the favouLrable therapeutic differential seen when some solid tumours are treated by hyperthermia (Field & Bleehen, 1979).…”

mentioning

confidence: 99%

A comparison of the response to hyperthermia of murine haemopoietic stem cells (CFU-S) and L1210 leukaemia cells: Enhanced killing of leukaemic cells in presence of normal marrow cells

Symonds¹,

Wheldon²,

Clarke³

et al. 1981

Br J Cancer

View full text Add to dashboard Cite

When the clonogenic survival of mouse haemopoietic stem cells (CFU-S) and leukaemia L1210 cells growth as ascites tumours are compared after being heated in vitro and assayed in vivo by spleen-colony assay, there is no significant difference in the terminal slopes of the survival curves. The shoulders of the survival curves differ, but this may be explained by differences in cell kinetics. By contrast, L1210 leukaemic marrow cells are considerably more susceptible to the lethal effects of hyperthermia (43 degrees C) than either normal marrow stem cells or L1210 leukaemic cells grown as ascites tumours. Moreover, the killing of L1210 ascites cells by hyperthermia can be enhanced by heating L1210 ascites cells with an equal number of normal marrow cells, or as upernatant removed from heated marrow cells. Most cells in lukaemic marrow are normal, and it is postulated that the increased thermal sensitivity of L1210 cells in leukaemic marrow is caused by diffusible factors (e.g. lysosomal enzymes) released by heating normal marrow cells. Images Fig. 8 Fig. 9

show abstract

Hyperthermia in the treatment of cancer

Cited by 263 publications

References 75 publications

Thermoradiotherapy planning: Integration in routine clinical practice

Thermoradiotherapy planning: Integration in routine clinical practice

Synergistic chemotherapy by combined moderate hyperthermia and photochemical internalization

A comparison of the response to hyperthermia of murine haemopoietic stem cells (CFU-S) and L1210 leukaemia cells: Enhanced killing of leukaemic cells in presence of normal marrow cells

Contact Info

Product

Resources

About